Leerink Partners maintains Insulet at Market Perform, raises price target to $167 from $143

Leerink Partners kept Insulet at Market Perform, raising its price target to $167 from $143, a 16.8% increase. This implies 1.2% upside from the Nov 4 close of $165.02. Recent analyst targets for Insulet range from $150 to $200.

Original reporting
Published Nov 5, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Insulet at Market Perform, raises price target to $167 from $143 — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst price target increase could prompt short covering and new buying.

02

Market read

Analyst upgrade may influence short-term price action for PINS.

03

What to watch

Potential competitive pressures and reimbursement challenges.

Relevance 7/10Novelty 6/10Timing: post-market

Background

Insulet Corp. (PINS) is a medical device company specializing in insulin pumps.

Market effects

May boost sentiment in the medical device sector.

Limited to US markets where Insulet trades.

Low global impact.

Counterpoint

Target raise may be premature if upcoming earnings miss expectations.

Key entities

  • Leerink Partners

    Equity research firm that raised the price target.

  • Insulet Corp.

    Manufacturer of insulin delivery devices.

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.

$PODDHighAI 8/10

What Insulet (PODD) Said on Its Q3 Earnings Call

Insulet (PODD) reported Q3 revenue of $842M, adjusted EPS of $1.99, and record gross margin of 74.2%. The company narrowed its 2026 revenue outlook to 21-22% growth and expects 2027 growth to be modestly below mid-teens. Insulet also announced a $1B increase to its share repurchase program and product updates, including Omnipod 6 and a type 2 diabetes system.